Vaccine and biotech stocks initially rallied on speculation about a broader outbreak, then cooled as officials downplayed pandemic risk. The CDC’s announcement that it has ended its hantavirus response likely reinforced public‑health reassurances and contributed to reduced investor concern about a wider outbreak.
Click a connection line between nodes to view confidence and evidence.